Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).

被引：0
|
作者：
Muller, Martin C.
Baccarani, Michele
Deininger, Michael W. N.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Talpaz, Moshe
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Timothy Piers
Haluska, Frank G.
Cortes, Jorge E.
机构：
[1] Univ Med Mannheim, Mannheim, Germany
[2] S Orsola Malpighi Univ Hosp, Bologna, Italy
[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[4] CHU Poitiers, Inserm CIC 1402, Poitiers, France
[5] Jena Univ Hosp, Jena, Germany
[6] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[7] Univ Adelaide, Adelaide, SA, Australia
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7053
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial
    Hochhaus, Andreas
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck. E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Muller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Conlan, Maureen
    Rivera, Victor M.
    Guilhot, Francois
    Deininger, Mochael W.
    Hughes, Timothy P.
    Shah, Neil P.
    Kantarjian, Hagop M.
    BLOOD, 2015, 126 (23)
  • [32] Comparison of PACE clinical trial versus real-world (RW) ponatinib (PON) prescribing and duration of therapy (DOT) in US chronic-phase chronic myeloid leukemia (CP-CML) patients (pts).
    Mauro, Michael J.
    McGarry, Lisa
    Yang, Mo
    Lustgarten, Stephanie
    Huang, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic -Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial
    Deininger, Michael W.
    Apperley, Jane F.
    Arthur, Christopher Kevin
    Chuah, Charles
    Hochhaus, Andreas
    De Lavallade, Hugues
    Lipton, Jeffrey H.
    Lomaia, Elza
    McCloskey, James K.
    Maness, Lori J.
    Mauro, Michael J.
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rosti, Gianantonio
    Rousselot, Philippe
    Undurraga, Soledad S.
    Lu, Vickie
    Vorog, Alexander
    Cortes, Jorge E.
    BLOOD, 2021, 138
  • [34] 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Talpaz, Moshe
    Baccarani, Michele
    Deininger, Michael W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Shah, Neil P.
    Lustgarten, Stephanie
    Santillana, Sergio
    Rivera, Victor M.
    Clackson, Tim
    Mueller, Martin C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S307 - S308
  • [35] Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)
    Jabbour, Elias
    Huang, Fei
    Zoratti, Michael J.
    Rutherford, Megan
    Moradian, Hoora
    Dalal, Mehul
    Ashaye, Ajibade
    Gordan, Lucio N.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S338 - S339
  • [36] 3-Year outcomes in patients with heavily calcified lesions undergoing percutaneous coronary intervention using cutting balloons
    Liu, Wei
    Yao, Yutong
    Jiang, Zhi
    Tian, Longhai
    Song, Bo
    Liu, Hui
    Deng, Shiyan
    Luo, Rui
    Wei, Fang
    BMC CARDIOVASCULAR DISORDERS, 2022, 22 (01)
  • [37] 3-Year outcomes in patients with heavily calcified lesions undergoing percutaneous coronary intervention using cutting balloons
    Wei Liu
    Yutong Yao
    Zhi Jiang
    Longhai Tian
    Bo Song
    Hui Liu
    Shiyan Deng
    Rui Luo
    Fang Wei
    BMC Cardiovascular Disorders, 22
  • [38] Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels
    Klamova, Hana
    Polakova, Katerina Machova
    Muzik, Jan
    Racil, Zdenek
    Zackova, Daniela
    Steinerova, Katerina
    Karas, Michal
    Faber, Edgar
    Demeckova, Eva
    Michalovicova-Sninska, Zuzana
    Voglova, Jaroslava
    Demitrovicova, L'udmila
    Mikuskova, Eva
    Tothova, Elena
    Chudej, Juraj
    Markuljak, Imrich
    Cmunt, Eduard
    Moravcova, Jana
    Dvorakova, Dana
    Michalova, Kyra
    Jarosova, Marie
    Stastna, Marketa Markova
    Cetkovsky, Petr
    Dusek, Ladislav
    Koza, Vladimir
    Trneny, Marek
    Indrak, Karel
    CANCER MEDICINE, 2013, 2 (02): : 216 - 225
  • [39] Impact of Dyslipidemia on 3-year Clinical Outcomes in Patients with Significant Coronary Artery Spasm
    Choi, Byoung Geol
    Rha, Seung-Woon
    Choi, Se Yeon
    Park, Yoonjee
    Goud, Akkala Raghavender
    Li, Hu
    Lee, Sunki
    Kim, Ji Bak
    Im, Sung Il
    Na, Jin Oh
    Choi, Cheol Ung
    Lim, Hong Euy
    Kim, Jin Won
    Kim, Eung Ju
    Park, Chang Gyu
    Seo, Hong Seog
    Oh, Dong Joo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : S53 - S53
  • [40] Survival Outcomes in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Third- or Subsequent Line (3L) Treatment
    Stellato, Daniel R.
    McGarry, Lisa
    Huang, Hui
    Hastings, Shaina
    Delea, Thomas E.
    Lipton, Jeffrey H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S311 - S312
12345